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Akt inhibitora b s t r a c t
The possibility of the pandemic spread of inﬂuenza viruses highlights the need for an effective cure for
this life-threatening disease. Inﬂuenza A virus, belonging to a family of orthomyxoviruses, is a nega-
tive-strand RNA virus which encodes 11 viral proteins. A numbers of intracellular signaling pathways
in the host cells interact with inﬂuenza the viral proteins, which affect various stages of viral infection
and replication.
In this study, we investigated how inhibition of Akt kinase activity impacts on inﬂuenza virus infection
by using ‘‘Akt-in’’, a peptide Akt inhibitor. In PR8 inﬂuenza-infected A549 cells, Akt interacted with the
NS1 (Non structural protein 1), and hence increased phosphorylation of Akt kinase activity and NS1.
Treatment of cells with either ‘‘TCL1- or TCL1b-based Akt-in’’ efﬁciently suppressed Akt kinase activity
while decreasing the levels of phosphorylated NS1; this, in turn, inhibited viral replication in a dose-
and time-dependent manner. The inhibitory effect on viral replication appears to not be due to inhibition
of the production of inﬂammatory cytokines, including IL-6 and IL-8, in the host cells. Inhibition of Akt
kinase activity in the host cells inhibited the efﬁciency of viral entry, which is associated with decreased
levels of phosphorylated glycogen synthase kinase 3, a substrate of Akt. Thus inhibition of Akt kinase
activity in host cells may have therapeutic advantages for inﬂuenza virus infection by inhibiting viral
entry and replication.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The serine/threonine kinase Akt, which belongs to the cAMP
dependent, cGMP dependent, and protein kinase C (AGC) group,
was originally identiﬁed from the Akt8 acute transforming retrovi-
rus, which causes mouse thymoma [1,2].
In response to various extracellular stimuli, Akt is activated by
the lipid products of phosphoinositide 30-kinase (PI3K), namely
PtdIns (3,4,5) P3 and its immediate breakdown product PtdIns
(3,4) P2; PI3K phosphorylates the 30-OH position of the inositol core
of inositol phospholipids [3,4]. The binding of PtdIns (3,4,5) P3 to
the Akt-pleckstrin homology (Akt-PH) domain within variable loop
1 (the loop between the b1 and b2 strands) and its subsequent
translocation to the plasma membrane, allows phosphoinositide-
dependent kinase-1 (PDK1) to access and trigger phosphorylation
at a threonine residue (Thr308) within the catalytic domain of
Akt [1,2,5]. The mTOR-Rictor complex 2 (TORC2) has also recently
been shown to be involved in a major activation mechanismunderlying the phosphorylation of Ser473 in the carboxy-terminal
hydrophobic motif [6].
Once activated, Akt controls downstream cellular responses,
including the regulation of activities related to anti-apoptosis, pro-
liferation, cell cycle, glycogen synthesis, angiogenesis, and telome-
rase. Thus, PI3K–Akt pathways underlie the pathogenesis of
various human diseases. It is noteworthy that the PI3K–Akt path-
way underlies clinical manifestation of different stages of infection
by virus such as Epstein–Barr, hepatitis C, hepatitis B, and human
immunodeﬁciency virus (HIV), as well as inﬂuenza virus [2,7,8].
In recent years, pandemic inﬂuenza caused by H1N1 avian
inﬂuenza viruses have emerged, and now appear to have spread
across many regions throughout the world [9]. The inﬂuenza virus
consists of eight segmented minus-stranded RNAs which encode
11 known proteins. A number of intracellular signaling pathways
in the host cells has been shown to interact with viral proteins, a
process that is critical for viral replication [9]. Among the 11 inﬂu-
enza proteins, non-structural protein 1 (NS1, encoded on segment
8), a 26-kDa protein, has been implicated in the regulation of
several biological functions, including regulation of apoptosis sup-
pression in the host immune responses, through NF-jB-dependent
mechanisms [10–12].
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action of inﬂuenza NS1 protein with Akt, a core intracellular sur-
vival regulator and the major effector molecules of PI3K [7]. The
RNA-binding domain of NS1 interacts with Akt-PH domain; this
consequently enhances Akt kinase activity and results in phos-
phorylation of NS1 at Thr215. The Akt-NS1 functional interaction
possibly facilitates the symbiotic relationship between the host
cells and the virus, promoting cell survival for inﬂuenza viral rep-
lication [7].
In addition to Akt, inﬂuenza NS1 is also known to interact with
the p85b regulatory subunit of PI3K by binding directly to the SH3
and C-terminal SH2 domain of p85; this consequently activates the
PI3K–Akt pathway [13]. Therefore, inﬂuenza A virus NS1 protein
activates the PI3K–Akt pathway in multiple steps during viral
infection, so modulating the cellular responses of host cells.
Various human host cell factors are known to be required for
inﬂuenza replication [14,15]. Intracellular PI3K–Akt pathways not
only regulate very early steps during viral entry, but also suppress
premature apoptosis at later stages of infection [8,9,13]. PI3K–Akt
pathways play a critical role in uptake during viral entry, preven-
tion of premature apoptosis, and viral RNA expression and RNP
localization [13,16,17]. Virally infected cells can presumably avoid
their own virus-induced death by effectively activating the PI3K–
Akt pathway, which may allow scavengers to control the host
cell-to-cell infectious process. Therefore, inhibitors of this cellular
signaling pathway could represent a new promising antiviral ther-
apy against inﬂuenza infection [8,15,18,19].
In this report, we pursued this proposed therapeutic interven-
tion by using Akt inhibitors ‘‘Akt-in’’ [20–22] to investigate and
clarify whether and how suppression of the PI3K–Akt pathway in
host cells has a beneﬁcial impact on controlling the inﬂuenza infec-
tion, with a view to therapeutic beneﬁt against inﬂuenza virus
infection.2. Materials and methods
2.1. Cell lines, viruses, antibodies and pharmacological inhibitors
A549 and MDCK cells (ATCC) were cultured in RPMI-1640
(Sigma) or DMEM (Sigma) supplemented with 10% FBS. Inﬂuenza
A/Puerto-rico/8/34 (H1N1, PR8) virus strain was provided by Dr.
Kida. LY294002 (Sigma), TAT-FLAG (YGRKKRRQRRR-DYKDDDDK),
TAT-TCL1-Akt-in (YGRKKRRQRRR-AVTDHPDRLWAWEKF) [20],
and TAT-TCL1b-Akt-in (YGRKKRRQRRR-RLGVPPGRLWIQRPG) [21]
were obtained from (MBL), Anti-Akt, anti-phospho-Ser473 Akt,
anti-phospho-Ser308Akt, anti-phospho-Akt substrate, anti-phos-
pho-GSK3a/b, anti-GSK3a/b antibodies (Cell Signaling Technol-
ogy), anti-a-tubulin antibody (Sigma), anti-Inﬂuenza A NS1
antibody (Santa Cruz), and nucleoprotein antibody (BEI resources)
were used in this study.2.2. Inﬂuenza virus infection and plaque assays
A549 cells (ATCC) were infected with PR8 virus (MOI = 0.1) for
1 h. The viral supernatant was replaced with RPMI-1640, BSA,
and trypsin. For the plaque assay, MDCK cells were incubated with
the viral culture supernatant for 1 h, overlaid with agarose, and the
numbers of plaques were counted.2.3. Co-immunoprecipitation experiment of PR8-infected cells
A549 cells were infected with PR8 (MOI = 1) for 18 h, harvested,
lysed, and immunoprecipitated with the indicated antibodies and
immunoblotted using anti-NS1 antibody [7].2.4. Immunoﬂuorescent staining
A549 cells were incubated with the indicated inhibitors for
30 min before PR8 infection (MOI = 0.1), ﬁxed, stained with the
indicated antibodies or DAPI, and examined using a confocal
microscopy (Fluoview FV-1000, Olympus).
2.5. Measurement of cytokines
The protein levels of IL-6 and IL-8 in the supernatant of PR8-
infected A549 cells were measured using ELISA MAX Deluxe Sets
(BioLegend).
2.6. Statistical analysis
Results were statistical analyzed using paired t-tests.3. Results
3.1. Inﬂuenza virus infection enhances Akt kinase activity in PR8-
infected A549 cells
The PI3K–Akt network has been shown to underlie clinical man-
ifestations of various stages of viral infection [2,7,13]. Previously,
we have shown that NS1 of inﬂuenza A virus interacts directly with
Akt and enhances Akt kinase activity [7].
Inﬂuenza virus NS1 has been shown to antagonize the cellular
immune response and is implicated in virulence by activating
PI3K–Akt signaling pathway as one of the major downstream effec-
tors of host cells that enhance efﬁcient replication [10,12,13].
These observations prompted us to examine how infections of cells
with PR8 inﬂuenza virus can alter the levels of Akt phosphorylation
and that of its substrate, NS1 [7]. To this end, A549 cells were
infected with PR8 and the levels of Akt and NS1 phosphorylation
were examined. Indeed, we found that PR8 infection of A549 cells
signiﬁcantly induced levels of Akt phosphorylation, which was
associated with increased phosphorylation of NS1 (Fig. 1A).
NS1 is also known to activate PI3K through its interaction with
p85b, a regulatory subunit of PI3K, resulting in the phosphoryla-
tion of Akt [11,23]. Highly conserved tyrosine motifs of NS1 play
a role in the interaction of this protein with p85b and in the acti-
vation of PI3K [24]. Given the observation that NS1 interacts
directly with Akt and enhances Akt kinase activity [7], the
enhanced phosphorylation of Akt and NS1 (Fig. 1A) is possibly
due to the direct interaction of endogenous Akt with NS1 in PR8-
infected A549 cells, as demonstrate by co-immunoprecipitation
assays (Fig. 1B).
3.2. Inhibition of Akt kinase activity by TCL1- or TCL1b-based peptide
inhibitors efﬁciently suppresses viral replication
Modulation of human host factors is important for regulating
inﬂuenza virus replication [14]. PI3K–Akt signaling is known to
play a role in various stages of inﬂuenza virus replication
[13,16,17]. Since Akt signaling involves many aspects of cellular
responses – such as those involving anti-apoptosis, proliferation,
protein translation, metabolism and cell cycle – PI3K–Akt path-
ways provide a promising therapeutic target for human viral infec-
tion [11,15]. Given the fact that PR8 infection induces the
activation of Akt and its viral protein substrate NS1, we next asked
how activation of Akt and NS1 may affect the viral replication upon
inﬂuenza infection.
Based on the structural–functional analysis of the TCL1-Akt pro-
tein complex, we previously identiﬁed a TCL1 and TCL1b-structure
based-peptide, named TCL1-Akt-in (a TCL1-based Akt inhibitor
Fig. 1. (A) Infection A549 cells with PR8 increased Akt kinase activity, which is associated with increased levels of NS1 phosphorylation. (B) Endogenous Akt co-
immunoprecipitated with inﬂuenza NS1 protein (lane4, second panel from the top) in PR8-infected A549 cells. Note that no NS1 protein could be immunoprecipitated by the
control antibody (lane1, top panels). Expression of the NS1 protein and endogenous Akt of the PR8-infected cells are shown in the lower panels as internal controls. (C)
Treatment of PR8-infected A549 cells with LY294002 (lane 2), TCL1-Akt-in (lane 4), or TCL1b-Akt-in (lane 5) efﬁciently inhibited phosphorylation of Akt along with decreased
levels of NS1 phosphorylation. (D) Treatment of PR8-infected A549 cells with LY294002 (lane 2), TCL1-Akt-in (lane 4), or TCL1b-Akt-in (lane 5) efﬁciently inhibited viral
replication in plaque assays. The pictures of the plaque phenotypes of each treatment were shown underneath.
N. Hirata et al. / Biochemical and Biophysical Research Communications 450 (2014) 891–898 893encompassing the bA strand of TCL1), and ‘‘TCL1b-Akt-in’’ (a
TCL1b-based Akt inhibitor). Both TCL1- and TCL1b-Akt-in inhibited
Akt kinase activity and, hence, suppressed proliferation of cancer
cells [20–22]. In order to suppress Akt kinase activity, we used
TCL1- or TCL1b-based Akt-in, a peptide Akt kinase inhibitor [20,21].LY294002, a classical PI3K inhibitor, is known to compete for
the ATP-binding site of the catalytic domain of lipid kinases.
LY294002 treatment efﬁciently inhibited phosphorylation of Akt
as well as that of NS1. Treatment of PR8-infected A549 cells with
TCL1-Akt-in (or TCL1b-Akt-in), efﬁciently inhibited phosphoryla-
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Akt, which remained unchanged after treatment of cells with
LY294002, TCL1-Akt-in, or TCL1b-Akt-in, the levels of NS1 expres-
sion appeared to be decreased, which may affect the decreased lev-
els of the phospho-NS1 observed in this experiment. Moreover,
treatment of PR8-infected A549 cells with LY294002, TCL1-Akt-in,
or TCL1b-Akt-in efﬁciently inhibited viral replication in plaque
assays (Fig. 1D)
3.3. Inhibition of Akt kinase activity by TCL1- or TCL1b-based peptide
inhibitors (Akt-in) efﬁciently suppresses viral replication in a dose-
and time-dependent manner
The inﬂuenza virus is considered to evade both innate and
adaptive immunity via the NS1 protein, during which viral NS1 is
known to activate PI3K signaling pathway as one of the major
downstream effectors that enhances efﬁcient replication [11–13].
Recent studies suggested that cellular signaling pathway inhibitors
may hold promise as antiviral therapy against inﬂuenza [15,25,26].Fig. 2. (A and B) Treatment of PR8-infected A549 cells with increased amount of TCL1
phosphorylation of Akt (third panel from the top) and NS1 (top panel). (C and D) Increas
inhibited virus replication in plaque assays.These observations prompted us to examine whether inhibition of
Akt kinase activity in the virus-infected host cells could represent a
potential therapeutic target against inﬂuenza viral infection.
Treatment of PR8-infected A549 cells with increased amounts
of TCL1-Akt-in (Fig. 2A) or TCL1b-Akt-in (Fig. 2B) correlated inver-
sely with the levels of phosphorylation of Akt and NS1, in a dose-
dependent manner. It is noteworthy that the levels of endogenous
Akt did not decrease with even with a TCL1-Akt-in concentration of
up to 50 lM. However, total NS1 levels seemed decrease after
treatment with 50 lM of TCL1- or TCL1b-Akt-in, which may also
have contributed to the decreased levels of the phosphorylated
form of NS1 that were observed in this experiment. The decreased
NS1 expression was consistent with that observed after treatment
of MK2206, an allosteric inhibitor of Akt [19]. To further evaluate
the effect of viral replication observed in the dose escalation treat-
ment, we conducted viral plaque assays. We found that indeed,
treatment with increased amount of TCL1-Akt-in (Fig. 2C) or
TCL1b-Akt-in (Fig. 2D) efﬁciently inhibited viral replication in a
dose-dependent manner.- Akt-in (panel A) or TCL1b-Akt-in (panel B) correlated inversely with the levels of
ed amounts of TCL1-Akt-in (panel C) or TCL1b-Akt-in (panel D) treatment efﬁciently
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stages of inﬂuenza virus infection [13,18], we next examined the
effect of TCL1- or TCL1b-Akt-in for during long-term treatment,
to evaluate the effect of phosphorylation of Akt and NS1 in the
PR8-infected A549 cells, using time-course experiment. Treatment
of PR8-infected A549 cells with TCL1-Akt-in or TCL1b-Akt-in efﬁ-
ciently inhibited the levels of phosphorylation of Akt at Ser473,
Thr308, and NS1 by 24 h, 48 h, and 72 h after PR8 infection
(Fig. 3A). The inhibitory effect of the kinase activity in the virus
infected host cells correlated markedly with inhibition of inﬂuenza
virus replication at 24 h, 48 h, and 72 h after the PR8 infection in
the plaque assays (Fig. 3B). These observations indicated thatFig. 3. (A) Treatment of PR8-infected A549 cells with TCL1-Akt-in or TCL1b-Akt-in efﬁcie
top), Thr308 (fourth panel from the top), and NS1 (top panel) at 24 h after infection of ce
Treatment of PR8-infected A549 cells with TCL1-Akt-in or TCL1b-Akt-in, but not control p
after infection of cells with PR8 inﬂuenza virus in plaque assays.TCL1- and TCL1b-based inhibitors can inhibit both the early phase
(virus attachment and/or viral entry) and late phase of PI3K-activa-
tion events (including production of inﬂammatory cytokines such
as IL-6 or IL-8) [13].
3.4. Inhibition of Akt kinase activity blocks viral entry without
inhibiting cytokine production in the host cells
Inﬂuenza viral infection is known to increase inﬂammatory
reaction, which promotes production of IL-6 or IL-8 [26–29]. In
order to evaluate the nature of inhibitory effect observed by treat-
ment of PR8-infected host cells with TCL1-Akt-in or TCL1b-Akt-in,ntly inhibited the levels of phosphorylation of Akt at Ser473 (third panel from the
lls with PR8 inﬂuenza virus (lanes 1–4), 48 h (lanes 5–8), and 72 h (lanes 9–12). (B)
eptide, efﬁciently inhibited the replication of inﬂuenza virus at 24 h, 48 h, and 72 h
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tant of PR8-infection of A549 cells. PR8 infection of A549 cells
markedly increased the production of both IL-6 and IL-8 approxi-
mately two- to threefold. Treatment of these cells with
LY294002, a PI3K inhibitor, suppressed the production of IL-6 or
IL-8, both of which are considered to be important inﬂammatory
cytokines for viral infection [26–29]. However, the culture super-
natant from TCL1-Akt-in- or TCL1b-Akt-in-treated PR8-infected
A549 cells showed no inhibition of IL-6 (Fig. 4A) or IL-8 production
(Fig. 4B). This observation suggested that, in contrast to LY294002,
inhibition of viral replication by TCL1-Akt-in or TCL1b-Akt-in is not
due to the inhibition of production of inﬂammatory cytokines suchFig. 4. (A) Quantiﬁcation of IL-6 in the culture supernatants of A549 cells infected with
supernatants of A549 cells infected with PR8 at a MOI = 0.1, used for plaque assays. (C) Ni
or anti-phospho-Akt antibodies and examined by confocal microscopy to determine the
(E) Quantiﬁcation of phosphorylated Akt from panels C (n = 10).as IL-6 or IL-8. The discrepancy is possibly due to the off-target
effect of LY294002, since LY294002, a classical PI3K inhibitor, pos-
sibly inhibits additional regulatory molecules other than Akt as
downstream effectors of PI3K, hence suppressing cell growth and
protein translation by inhibiting p70S6 kinase [1,2,4]. In contrast,
Akt-in, which speciﬁcally inhibits association of PtdIns with Akt,
has potent inhibitory effects speciﬁc to Akt kinase, one of the major
downstream effector molecules of PI3K [20].
To further examine the nature of the inhibition of viral replica-
tion by TCL1-Akt-in or TCL1b-Akt-in, we next investigated the
mechanisms underlying the dose- and time-dependent inhibition
observed in the plaque assays. We used nucleoprotein, a multi-PR8 at a MOI = 0.1, used for plaque assays. (B) Quantiﬁcation of IL-8 in the culture
nety minutes after PR8-infection of A549 cells were stained with anti-nucleoprotein
uptake of inﬂuenza virus. (D) Quantiﬁcation of nucleoprotein from panel C (n = 10).
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as a detection marker for inﬂuenza viral infection [30]. Consistent
with the immunoblot results shown in Fig. 1A, upon double posi-
tive immunostaining of both anti-nucleoprotein and anti-phos-
pho-Akt antibodies by confocal microscopy, PR8-infected A549
cells showed a marked increase in phosphorylation of Akt
(Fig. 4C). Treatment of cells with TCL1- or TCL1b-Akt-in decreased
the levels of phospho-Akt, which appeared to be correlated well
with the decreased levels of inﬂuenza virus uptake, as determined
by the red signal of the nucleoprotein (Fig. 4C–E). Since PI3K–Akt
signaling pathways in host cells can be activated by inﬂuenza
NS1 [7,11,23,24], the inhibition of viral uptake/entry may account
for the decreased expression of inﬂuenza virus NS1, hence inhib-
ited the levels of phospho-Akt in PR8-infected A549 host cells.4. Discussion
In this study, we showed treatment of cells with either ‘‘TCL1-
or TCL1b-based Akt-in’’ [20,21], efﬁciently suppressed Akt kinase
activity while decreasing the levels of phosphorylated NS1; this,
in turn, inhibited viral entry and replication without inhibiting
the production of inﬂammatory cytokines.
For replication and transcription of the inﬂuenza virus genome,
various host cell-derived factors are required such as PI3K–Akt
pathways [25,26]. Hence, Akt inhibitors are an attractive target
for therapy against human viral infection. Several attempts have
been made to develop Akt inhibitors [2]. We have previously iden-
tiﬁed a peptide, named ‘‘Akt-in’’, which interacts with Akt and spe-
ciﬁcally inhibits its kinase activity [20,22]. The TCL1- or TCL1b-
based inhibitor ‘‘Akt-in’’ effectively inhibited the Akt kinase activi-
ties of PR8-infected host cells, and consequently suppressed viral
uptake and replication without inhibiting the production of inﬂam-
matory cytokines. Our observations are consistent with a recent
report by Deniscova that MK2206, an allosteric Akt inhibitor,
inhibited NS1 expression and, hence, prevented H1N1 inﬂuenza
infection [19]. We showed that treatment with the Akt inhibitor
suppressed GSK3 phosphorylation levels (Figs. 2 and 3); this was
in agreement with the report that GSK3-b, an Akt substrate [31],
is a key regulatory molecule for inﬂuenza viral entry [11,14,25].
Activated Akt phosphorylates GSK3, reducing its activity, which
lead to enhance production of glycogen [31].
H1N1 avian inﬂuenza virus-induced disease has emerged and
now appears to be present in a sufﬁcient number of countries to
be considered a major global health concern. Multiple cellular sig-
naling pathways are involved in inﬂuenza virus replication
[14,15,18,26]. In addition to direct involvement in tumorigenesis
by genetic alterations of human cancers, the PI3K–Akt network
also underlies the clinical manifestation of various stages of viral
infection [2,13,16]. By effectively activating the PI3K–Akt network,
virally infected cells can presumably avoid their own virus-
induced death. Inhibiting anti-apoptotic PI3K–Akt signaling may,
thus, allow scavengers to control the various stages of host cell-
to-cell infectious processes [9,19]. The PI3K–Akt–mTOR pathway
has also been suggested to play a role in the regulation of Macro-
autophagy [32], which is involved in various stages of viral infec-
tions by controlling the innate immunity [33–35]. However, in
our preliminary experiments using Akt inhibitors did not alter
the induction of autophagy in PR8-infected A549 cells, excluding
the possibilities of the involvement of autophagy in this process.
In this study, we showed that the TCL1- and TCL1b-based inhib-
itors effectively inhibited Akt kinase activity in PR8-infected host
cells, and consequently effectively suppressed viral entry, NS1
expression, without affecting the cytokine production. These
observations supported that TCL1- and TCL1b-based inhibitors
can inhibit both early phase (viral entry) and late phase of viralinfection events (viral genome replication). In contrast to the
anti-viral pharmacological reagents targeting the inﬂuenza viral
particles, inhibition of Akt kinase activity by Akt-in contributed
to suppress multiple steps of inﬂuenza virus infection without
affecting the immune reaction of the host cells. Thus, combination
usage of speciﬁc inhibitors for Akt with anti-viral pharmacological
reagents may have a beneﬁt against inﬂuenza infection, a life
threatening human disease. The observation will facilitate the
design of speciﬁc inhibitors for Akt, a core intra-cellular survival
factor underlying inﬂuenza infections.
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